AsclepiX Therapeutics Completes Enrollment in DISCOVER Trial for Neovascular Age-Related Macular Degeneration (nAMD)
06 Mayo 2024 - 5:00AM
AsclepiX Therapeutics, Inc., a clinical-stage biopharmaceutical
company leveraging computational biology from Johns Hopkins to
identify and develop peptides for improved treatments of retinal
diseases, today announced the completion of enrollment into the
DISCOVER trial (NCT05859776). Fifteen patients have completed
enrollment in the trial for AXT107 (gersizangitide). The objectives
of the trial are to evaluate the safety and tolerability of three
dose strengths of AXT107 [125 µg (n=3), 250 µg (n=3), and 500 µg
(n=9)] and to determine the bioactivity and duration of action when
injected suprachoroidally. Secondary endpoints will include
efficacy as assessed by central subfield thickness (CST) and
best-corrected visual acuity (BCVA). Following a single injection
of AXT107, to date, no patient has shown any remarkable safety
findings.
“I would like to thank the team and sites for their unwavering
commitment, collaborative spirit, and meticulous execution they
brought to the enrollment of the DISCOVER trial,” said Robert J.
Dempsey, Chief Executive Officer, AsclepiX Therapeutics. “Rapid
enrollment was a tribute to the partnership of our principal
investigators Drs. David Almeida, William Bridges, Sabin Dang, and
David Lally who played a critical role in achieving this
significant milestone for patients.”
AsclepiX’s lead clinical candidate, integrin regulating peptide
AXT107, has a novel mechanism of action that inhibits
neovascularization, reduces vascular permeability, and suppresses
vascular inflammation. Given as a microparticulate suspension
suitable for suprachoroidal injection, AXT107 is designed to
maintain sustained biological activity with one injection well
beyond the current standard of care.
About AXT107
AXT107 inhibits pro-angiogenic vascular endothelial growth
factor receptor 2 (VEGFR2) and activates the vessel stabilizing
receptor tyrosine kinase (Tie2), the two validated pathways for the
treatment of retinal vascular diseases. Both pathways are mediated
by the interaction of AXT107 with integrin αvβ3 and integrin α5β1.
AXT107 is formulated as a microparticulate suspension suitable for
intraocular injection.
The Tie2 effects of AXT107 complement those of the anti-VEGF
action, with the potential to have greater improvement in vision
gains as well as reduction of vascular permeability and suppression
of inflammation. Due to its inherent low aqueous solubility, AXT107
administered intraocularly can potentially provide substantial
durability, which could dramatically reduce the treatment burden
associated with the current standard of care.
About AsclepiX Therapeutics, Inc.
AsclepiX Therapeutics, Inc. is a clinical-stage
biopharmaceutical company using computational biology to identify
potent peptide regulators of vascular homeostasis with the lead
candidate, AXT107, in retinal diseases. AsclepiX was founded by
Johns Hopkins University School of Medicine researchers, initially
licensing their groundbreaking portfolio of vascular homeostatic
peptides and technologies. For more information, please visit:
www.asclepix.com
AsclepiX Media Contact:
Christie Markowitz
cmarkowitz@asclepix.com
Source: AsclepiX Therapeutics, Inc.